Ananda Pharma Plc — Share Issue/Capital Change 2024

Dec 11, 2024

National Storage Mechanism | Additional information

RNS Number : 5863P

Ananda Developments PLC

11 December 2024

11 December 202 4

ANANDA DEVELOPMENTS PLC  

("Ananda" or the "Company")  

Subscription to raise £150,000

Ananda Developments plc (AQSE: ANA), a company focused on the development of cannabinoid based therapies for the treatment of a range of complex conditions, is pleased to announce that it has successfully raised £150,000 from new shareholders by way of a subscription (the "Subscription") of 42,857,142 new Ordinary Shares (the "Subscription Shares") at a price of 0.35 pence each (the "Issue Price").

The proceeds of the Subscription will be used for general working capital and progressing its patent and regulatory workstreams.

Ananda's CEO, Melissa Sturgess commented: "We are delighted to welcome more long-term investors to Ananda.  The funds will be put to good use in our mission to deliver regulated cannabinoid-based medicines to patients alongside the over £2 million we successfully raised in September ." 

Admission and Total Voting Rights

An application has been made to the Aquis Stock Exchange for the Subscription Shares to be admitted to trading on AQSE with effect from 8a.m. on or around 16 December 2024 ("Admission"). The Subscription Shares will rank pari passu with the existing Ordinary Shares.

Following Admission, the Company will have 4,299,146,581 Ordinary Shares in issue, each share carrying the right to one vote. This figure of 4,299,146,581 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

To stay abreast of the latest developments at Ananda, we encourage you to follow our social media channels which are:  

·              Investor Hub: investors.anandadevelopments.com

·              Instagram: https://instagram.com/anandadevelopments?igshid=YmMyMTA2M2Y=       

·              LinkedIn : https://www.linkedin.com/company/anadevelopments/       

·              Twitter : https://twitter.com/AnandaPlc

·              Investor Meet Company: https://www.investormeetcompany.com/ananda-developments-plc/register-investor

-Ends-  

The Directors of the Company accept responsibility for the contents of this announcement.  

ANANDA DEVELOPMENTS PLC	+44 (0)7463 686 497
	[email protected]
Chief Executive Officer
Melissa Sturgess
Finance Director
Jeremy Sturgess-Smith
SP ANGEL CORPORATE FINANCE LLP	+44 (0)20 3470 0470
Corporate Finance
Richard Morrison
Caroline Rowe
Corporate Broking
Abigail Wayne
Rob Rees
Yellow Jersey PR (media enquiries) Sarah MacLeod Charles Goodwin Zara McKinlay	+44 (0)20 3004 9512 [email protected]

About Ananda Developments  

Ananda is an AQSE-listed life sciences company focused on the research and clinical development of CBD-based therapies for a range of complex inflammatory pain conditions.

For more information, please visit: https://anandadevelopments.com

Market Abuse Regulation (MAR) Disclosure  

The information contained within this announcement is deemed by the Company to constitute inside information. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.  

https://investors.anandadevelopments.com/link/WrvwYP

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXTMBPTMTABBAI